{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:06:49Z","timestamp":1791443209106,"version":"4.3.3"},"reference-count":84,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Pilot & Feasibility Grant from the Consortium for Fibrosis Research and Translation, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA"},{"name":"T32","award":["NIDDK 5T32DK007135"],"award-info":[{"award-number":["NIDDK 5T32DK007135"]}]},{"name":"T32","award":["NIGMS 5T32GM007635"],"award-info":[{"award-number":["NIGMS 5T32GM007635"]}]}],"content-domain":{"domain":["kidney-international.theisn.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.kint.2018.06.025","type":"journal-article","created":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T13:38:09Z","timestamp":1537537089000},"page":"1127-1140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["CD8+ T cells modulate autosomal dominant polycystic kidney disease progression"],"prefix":"10.1016","volume":"94","author":[{"given":"Emily K.","family":"Kleczko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth H.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan C.","family":"Tyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth B.","family":"Furgeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie L.","family":"Bullock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Altmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berenice Y.","family":"Gitomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary C.M.","family":"Weiser-Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel B.","family":"Chonchol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric T.","family":"Clambey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael A.","family":"Nemenoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Hopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2018.06.025_bib1","first-page":"S93","article-title":"Mechanisms of progression in autosomal dominant polycystic kidney disease","volume":"63","author":"Grantham","year":"1997","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2018.06.025_bib2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2215\/CJN.00330705","article-title":"Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes","volume":"1","author":"Grantham","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.06.025_bib3","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1681\/ASN.2015050583","article-title":"Predicted mutation strength of nontruncating PKD1 mutations aids genotype-phenotype correlations in autosomal dominant polycystic kidney disease","volume":"27","author":"Heyer","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.06.025_bib4","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","article-title":"Mutations in GANAB, encoding the glucosidase IIalpha subunit, cause autosomal-dominant polycystic kidney and liver disease","volume":"98","author":"Porath","year":"2016","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.kint.2018.06.025_bib5","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","article-title":"Clinical practice. Autosomal dominant polycystic kidney disease","volume":"359","author":"Grantham","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.06.025_bib6","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0272-6386(83)80044-4","article-title":"Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935-1980","volume":"2","author":"Iglesias","year":"1983","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.06.025_bib7","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000421651","article-title":"Genetic heterogeneity of polycystic kidney disease in Europe","volume":"97","author":"Peters","year":"1992","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.kint.2018.06.025_bib8","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2018.06.025_bib9","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.06.025_bib10","first-page":"806","article-title":"Analysis of causes of mortality in patients with autosomal dominant polycystic kidney disease: a single center study","volume":"20","author":"Rahman","year":"2009","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.kint.2018.06.025_bib11","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1053\/ajkd.2001.27720","article-title":"Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality","volume":"38","author":"Perrone","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.06.025_bib12","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1172\/JCI72272","article-title":"Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease","volume":"124","author":"Harris","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2018.06.025_bib13","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.06.025_bib14","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.06.025_bib15","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.06.025_bib16","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2018.06.025_bib17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/1573402111309010008","article-title":"Experimental therapies and ongoing clinical trials to slow down progression of ADPKD","volume":"9","author":"Irazabal","year":"2013","journal-title":"Curr Hypertens Rev"},{"key":"10.1016\/j.kint.2018.06.025_bib18","unstructured":"Harris PC, Torres VE. Polycystic kidney disease, autosomal dominant. GeneReviews. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1246\/. Published January 10, 2002; updated July 19, 2018. Accessed July 20,\u00a02018."},{"key":"10.1016\/j.kint.2018.06.025_bib19","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.272.5266.1339","article-title":"PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein","volume":"272","author":"Mochizuki","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.kint.2018.06.025_bib20","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/0092-8674(94)90137-6","article-title":"The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. The European Polycystic Kidney Disease Consortium","volume":"77","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.kint.2018.06.025_bib21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/jmg.30.7.583","article-title":"Childhood onset autosomal dominant polycystic kidney disease in sibs: clinical picture and recurrence risk. German Working Group on Paediatric Nephrology (Arbeitsgemeinschaft fuer Padiatrische Nephrologie)","volume":"30","author":"Zerres","year":"1993","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.kint.2018.06.025_bib22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJMc0801868","article-title":"Perinatal deaths in a family with autosomal dominant polycystic kidney disease and a PKD2 mutation","volume":"359","author":"Bergmann","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.06.025_bib23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(98)03495-3","article-title":"Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group","volume":"353","author":"Hateboer","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2018.06.025_bib24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/j.ackd.2009.12.004","article-title":"Determinants of renal disease variability in ADPKD","volume":"17","author":"Harris","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.kint.2018.06.025_bib25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ki.2009.128","article-title":"Autosomal dominant polycystic kidney disease: the last 3 years","volume":"76","author":"Torres","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.06.025_bib26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ng1076","article-title":"Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells","volume":"33","author":"Nauli","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2018.06.025_bib27","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature17426","article-title":"Primary cilia are not calcium-responsive mechanosensors","volume":"531","author":"Delling","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.kint.2018.06.025_bib28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nature12833","article-title":"Primary cilia are specialized calcium signalling organelles","volume":"504","author":"Delling","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.kint.2018.06.025_bib29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0272-6386(12)80507-5","article-title":"Polycystic kidney disease: neoplasia in disguise","volume":"15","author":"Grantham","year":"1990","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.06.025_bib30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrneph.2015.46","article-title":"The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease","volume":"11","author":"Seeger-Nukpezah","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2018.06.025_bib31","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.kint.2018.06.025_bib32","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1681\/ASN.V571462","article-title":"Proliferative activity of cyst epithelium in human renal cystic diseases","volume":"5","author":"Nadasdy","year":"1995","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.06.025_bib33","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1093\/hmg\/ddn180","article-title":"Loss of polycystin-1 causes centrosome amplification and genomic instability","volume":"17","author":"Battini","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.kint.2018.06.025_bib34","first-page":"169","article-title":"Genomic instability in patients with autosomal-dominant polycystic kidney disease","volume":"41","author":"Li","year":"2013","journal-title":"J\u00a0Int Med Res"},{"key":"10.1016\/j.kint.2018.06.025_bib35","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1172\/JCI119147","article-title":"Loss of the polycystic kidney disease (PKD1) region of chromosome 16p13 in renal cyst cells supports a loss-of-function model for cyst pathogenesis","volume":"99","author":"Brasier","year":"1997","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2018.06.025_bib36","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nm.3092","article-title":"Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy","volume":"19","author":"Rowe","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2018.06.025_bib37","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1681\/ASN.2015020132","article-title":"Food restriction ameliorates the development of polycystic kidney disease","volume":"27","author":"Warner","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.06.025_bib38","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1097\/01.ASN.0000088720.61783.19","article-title":"Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease","volume":"14","author":"Zheng","year":"2003","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.06.025_bib39","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nm1783","article-title":"A\u00a0tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease","volume":"14","author":"Li","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2018.06.025_bib40","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/nep.12045","article-title":"Role of interstitial inflammation in the pathogenesis of polycystic kidney disease","volume":"18","author":"Ta","year":"2013","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.kint.2018.06.025_bib41","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1681\/ASN.2011010084","article-title":"Macrophages promote cyst growth in polycystic kidney disease","volume":"22","author":"Karihaloo","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.06.025_bib42","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/ki.2012.446","article-title":"Macrophages promote polycystic kidney disease progression","volume":"83","author":"Swenson-Fields","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.06.025_bib43","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1681\/ASN.V10122534","article-title":"Clinical and pathologic findings in two new allelic murine models of polycystic kidney disease","volume":"10","author":"Vogler","year":"1999","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.06.025_bib44","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/ki.1992.413","article-title":"Renal histology in polycystic kidney disease with incipient and advanced renal failure","volume":"42","author":"Zeier","year":"1992","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.06.025_bib45","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/01.ASN.0000109782.28991.26","article-title":"Chymase-like angiotensin II-generating activity in end-stage human autosomal dominant polycystic kidney disease","volume":"15","author":"McPherson","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.06.025_bib46","doi-asserted-by":"crossref","first-page":"830","DOI":"10.2353\/ajpath.2007.060455","article-title":"Involvement of hypoxia-inducible transcription factors in polycystic kidney disease","volume":"170","author":"Bernhardt","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.kint.2018.06.025_bib47","first-page":"399","article-title":"Comparative effects of germfree and ambient environments on the development of cystic kidney disease in CFWwd mice","volume":"103","author":"Werder","year":"1984","journal-title":"J\u00a0Lab Clin Med"},{"key":"10.1016\/j.kint.2018.06.025_bib48","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/hep.28382","article-title":"Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis","volume":"63","author":"Locatelli","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.kint.2018.06.025_bib49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1189\/jlb.1212631","article-title":"At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy","volume":"94","author":"Callahan","year":"2013","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.kint.2018.06.025_bib50","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.kint.2018.06.025_bib51","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.kint.2018.06.025_bib52","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10555-010-9223-6","article-title":"Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity","volume":"29","author":"DeNardo","year":"2010","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.kint.2018.06.025_bib53","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2018.06.025_bib54","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1001\/jamaoncol.2017.1588","article-title":"Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials","volume":"3","author":"Long","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.kint.2018.06.025_bib55","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1172\/JCI64313","article-title":"Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity","volume":"122","author":"Hopp","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2018.06.025_bib56","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/ki.2008.686","article-title":"Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease","volume":"75","author":"Rossetti","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.06.025_bib57","first-page":"3399","article-title":"A\u00a0role of interferon-gamma (IFN-gamma) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-gamma-deficient mice","volume":"61","author":"Nakajima","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.kint.2018.06.025_bib58","doi-asserted-by":"crossref","first-page":"e0172821","DOI":"10.1371\/journal.pone.0172821","article-title":"Tissue-specific regulation of CXCL9\/10\/11 chemokines in keratinocytes: implications for oral inflammatory disease","volume":"12","author":"Marshall","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2018.06.025_bib59","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1172\/JCI93565","article-title":"Resisting fatal attraction: a glioma oncometabolite prevents CD8+ T cell recruitment","volume":"127","author":"Lucca","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2018.06.025_bib60","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation\u2014a target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.kint.2018.06.025_bib61","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/bjc.2016.172","article-title":"CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer","volume":"115","author":"Bronger","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.kint.2018.06.025_bib62","doi-asserted-by":"crossref","first-page":"89998","DOI":"10.18632\/oncotarget.21286","article-title":"Interferon-inducible CXC-chemokines are crucial immune modulators and survival predictors in colorectal cancer","volume":"8","author":"Kistner","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.kint.2018.06.025_bib63","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1002\/cam4.934","article-title":"CXCL9: evidence and contradictions for its role in tumor progression","volume":"5","author":"Ding","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.kint.2018.06.025_bib64","doi-asserted-by":"crossref","first-page":"F397","DOI":"10.1152\/ajprenal.00310.2002","article-title":"Immortalized epithelial cells from human autosomal dominant polycystic kidney cysts","volume":"285","author":"Loghman-Adham","year":"2003","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2018.06.025_bib65","first-page":"735","article-title":"Antiproliferative effects of four different cytokines on renal carcinoma cell lines","volume":"15","author":"Buszello","year":"1995","journal-title":"Anticancer Res"},{"key":"10.1016\/j.kint.2018.06.025_bib66","doi-asserted-by":"crossref","first-page":"7673","DOI":"10.1073\/pnas.93.15.7673","article-title":"Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma","volume":"93","author":"Bromberg","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2018.06.025_bib67","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.0818-9641.2004.01243.x","article-title":"T\u00a0cell activation: in\u00a0vivo veritas","volume":"82","author":"Fazekas de St Groth","year":"2004","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.kint.2018.06.025_bib68","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2567.1999.00738.x","article-title":"CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor","volume":"97","author":"Borrego","year":"1999","journal-title":"Immunology"},{"key":"10.1016\/j.kint.2018.06.025_bib69","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/ki.1997.12","article-title":"Th1 responsiveness to nephritogenic antigens determines susceptibility to crescentic glomerulonephritis in mice","volume":"51","author":"Huang","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.06.025_bib70","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.4049\/jimmunol.139.4.1303","article-title":"Cellular and humoral immunity to Leishmania major in genetically susceptible mice after in\u00a0vivo depletion of L3T4+ T cells","volume":"139","author":"Sadick","year":"1987","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.kint.2018.06.025_bib71","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/hmg\/11.15.1731","article-title":"Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant","volume":"11","author":"Muto","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.kint.2018.06.025_bib72","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1194\/jlr.P042176","article-title":"Bioactive lipid mediators in polycystic kidney disease","volume":"55","author":"Klawitter","year":"2014","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.kint.2018.06.025_bib73","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2215\/CJN.04140510","article-title":"Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease","volume":"6","author":"Menon","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.06.025_bib74","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/nep.12153","article-title":"Renal macrophages in autosomal recessive polycystic kidney disease","volume":"18","author":"Mrug","year":"2013","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.kint.2018.06.025_bib75","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.kint.2018.06.025_bib76","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.kint.2018.06.025_bib77","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/cei.13081","article-title":"Immune checkpoint inhibitors: new strategies to checkmate cancer","volume":"191","author":"Wilson","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.kint.2018.06.025_bib78","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/bs.ai.2015.12.003","article-title":"Tumor and host factors controlling antitumor immunity and efficacy of cancer immunotherapy","volume":"130","author":"Spranger","year":"2016","journal-title":"Adv Immunol"},{"key":"10.1016\/j.kint.2018.06.025_bib79","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.kint.2018.06.025_bib80","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000455014","article-title":"Adverse renal effects of immune checkpoint inhibitors: a narrative review","volume":"45","author":"Wanchoo","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2018.06.025_bib81","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2326-6066.CIR-17-0220","article-title":"Durable Clinical benefit in metastatic renal cell carcinoma patients who discontinue PD-1\/PD-L1 therapy for immune-related adverse events","volume":"6","author":"Martini","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.kint.2018.06.025_bib82","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1158\/1078-0432.CCR-12-2625","article-title":"Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody","volume":"19","author":"Lipson","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.kint.2018.06.025_bib83","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.88646","article-title":"Activating transcription factor-4 promotes mineralization in vascular smooth muscle cells","volume":"1","author":"Masuda","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.kint.2018.06.025_bib84","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1158\/1541-7786.MCR-06-0095","article-title":"Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines","volume":"4","author":"Coldren","year":"2006","journal-title":"Mol Cancer Res"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253818304824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253818304824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T08:44:46Z","timestamp":1693903486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253818304824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":84,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0085253818304824"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2018.06.025","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD8+ T cells modulate autosomal dominant polycystic kidney disease progression","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2018.06.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}